MXPA05001585A - Nuevo uso de derivados de benzotiazol. - Google Patents
Nuevo uso de derivados de benzotiazol.Info
- Publication number
- MXPA05001585A MXPA05001585A MXPA05001585A MXPA05001585A MXPA05001585A MX PA05001585 A MXPA05001585 A MX PA05001585A MX PA05001585 A MXPA05001585 A MX PA05001585A MX PA05001585 A MXPA05001585 A MX PA05001585A MX PA05001585 A MXPA05001585 A MX PA05001585A
- Authority
- MX
- Mexico
- Prior art keywords
- novel use
- benzothiazole derivatives
- formula
- disclosed
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere al uso de compuestos de formula (1), en donde X, A, B, D, R1 y R2 son como se definen en la especificacion y sales del los mismos farmaceuticamente aceptables, en la manufactura de un medicamento para el tratamiento o profilaxis de enfermedades o condiciones en las cuales la inhibicion de la actividad de cinasa Itk es benefica. Tambien se describen ciertos nuevos compuestos de formula (I), junto con los procesos para su preparacion, composiciones que los contienen y su uso en terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202429A SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Novel Compounds |
PCT/SE2003/001271 WO2004016600A1 (en) | 2002-08-14 | 2003-08-13 | Novel use of benzothiazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05001585A true MXPA05001585A (es) | 2005-04-25 |
Family
ID=20288724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05001585A MXPA05001585A (es) | 2002-08-14 | 2003-08-13 | Nuevo uso de derivados de benzotiazol. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060106015A1 (es) |
EP (1) | EP1539723B1 (es) |
JP (1) | JP2006504672A (es) |
KR (1) | KR20060002728A (es) |
CN (1) | CN1675189A (es) |
AT (1) | ATE327225T1 (es) |
AU (1) | AU2003248587A1 (es) |
BR (1) | BR0313407A (es) |
CA (1) | CA2495492A1 (es) |
DE (1) | DE60305514D1 (es) |
IL (1) | IL166412A0 (es) |
MX (1) | MXPA05001585A (es) |
NO (1) | NO20051263L (es) |
SE (1) | SE0202429D0 (es) |
WO (1) | WO2004016600A1 (es) |
ZA (1) | ZA200501098B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026316A2 (en) * | 2004-08-26 | 2006-03-09 | Wyeth | Prodrug substituted benzoxazoles as estrogenic agents |
NZ560969A (en) | 2005-02-17 | 2010-08-27 | Albany Molecular Res Inc | Benzoxazole carboxamides for treating chemotherapy-induced vomiting and irritable bowel syndrome |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
WO2007019417A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
ATE514663T1 (de) * | 2007-05-07 | 2011-07-15 | Siemens Ag | Keramisches pulver, keramische schicht und schichtsystem mit pyrochlorphase und oxiden |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CN101910158A (zh) * | 2007-10-25 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 可用于治疗细胞增殖性病症的吡啶衍生物和吡嗪衍生物 |
EA021424B1 (ru) | 2008-12-19 | 2015-06-30 | Сертрис Фармасьютикалз, Инк. | Тиазолопиридиновые соединения, регулирующие сиртуин |
WO2013153539A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
CA2928721C (en) | 2013-10-25 | 2020-12-22 | Pharmacyclics Llc | Use of ibrutinib for treating and preventing chronic graft versus host disease |
WO2016144635A1 (en) | 2015-03-06 | 2016-09-15 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a ras mutation |
MA45973A (fr) | 2015-08-31 | 2019-06-26 | Pharmacyclics Llc | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |
SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
CN110139669A (zh) | 2016-11-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | T细胞疗法和btk抑制剂的组合疗法 |
KR102279347B1 (ko) | 2016-12-15 | 2021-07-21 | 한국생명공학연구원 | 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2018111049A1 (ko) * | 2016-12-15 | 2018-06-21 | 한국생명공학연구원 | 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물 |
US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
SG11202006985TA (en) | 2018-01-24 | 2020-08-28 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
HUE057970T2 (hu) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
JP7410877B2 (ja) | 2018-05-03 | 2024-01-10 | ジュノー セラピューティクス インコーポレイテッド | キメラ抗原受容体(car)t細胞療法とキナーゼ阻害剤の併用療法 |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE581862A (es) * | 1958-08-22 | |||
DE2145178C3 (de) * | 1970-09-11 | 1975-12-11 | Tokyo Tanabe Co., Ltd., Tokio | 2-Phenyl-5-oder -6-benzothiazolylessigsäure-Verblndungen |
JPS4932855B1 (es) * | 1971-08-03 | 1974-09-03 | ||
DD150059A1 (de) * | 1980-04-07 | 1981-08-12 | Horst Hartmann | Verfahren zur herstellung von hydroxyarylazolen |
JPS62221679A (ja) * | 1986-03-19 | 1987-09-29 | Santen Pharmaceut Co Ltd | ベンゾチアゾリン誘導体 |
DE4030511A1 (de) * | 1990-09-27 | 1992-04-02 | Basf Ag | Hochtemperaturbestaendige, benzthiazolhaltige polyarylether |
US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
NZ503491A (en) * | 1997-11-10 | 2002-08-28 | Bristol Myers Squibb Co | 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors |
WO2001074810A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
JP2002306916A (ja) * | 2001-01-26 | 2002-10-22 | Toray Ind Inc | エアフィルタユニット |
-
2002
- 2002-08-14 SE SE0202429A patent/SE0202429D0/xx unknown
-
2003
- 2003-08-13 CN CNA038191393A patent/CN1675189A/zh active Pending
- 2003-08-13 AT AT03788208T patent/ATE327225T1/de not_active IP Right Cessation
- 2003-08-13 AU AU2003248587A patent/AU2003248587A1/en not_active Abandoned
- 2003-08-13 WO PCT/SE2003/001271 patent/WO2004016600A1/en active IP Right Grant
- 2003-08-13 MX MXPA05001585A patent/MXPA05001585A/es unknown
- 2003-08-13 KR KR1020057002297A patent/KR20060002728A/ko not_active Application Discontinuation
- 2003-08-13 CA CA002495492A patent/CA2495492A1/en not_active Abandoned
- 2003-08-13 US US10/524,124 patent/US20060106015A1/en not_active Abandoned
- 2003-08-13 BR BR0313407-5A patent/BR0313407A/pt not_active Application Discontinuation
- 2003-08-13 EP EP03788208A patent/EP1539723B1/en not_active Expired - Lifetime
- 2003-08-13 JP JP2004528996A patent/JP2006504672A/ja active Pending
- 2003-08-13 DE DE60305514T patent/DE60305514D1/de not_active Expired - Lifetime
-
2005
- 2005-01-20 IL IL16641205A patent/IL166412A0/xx unknown
- 2005-02-07 ZA ZA200501098A patent/ZA200501098B/xx unknown
- 2005-03-11 NO NO20051263A patent/NO20051263L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1539723B1 (en) | 2006-05-24 |
DE60305514D1 (de) | 2006-06-29 |
IL166412A0 (en) | 2006-01-15 |
AU2003248587A1 (en) | 2004-03-03 |
ZA200501098B (en) | 2006-12-27 |
NO20051263L (no) | 2005-05-12 |
JP2006504672A (ja) | 2006-02-09 |
SE0202429D0 (sv) | 2002-08-14 |
US20060106015A1 (en) | 2006-05-18 |
WO2004016600A1 (en) | 2004-02-26 |
ATE327225T1 (de) | 2006-06-15 |
BR0313407A (pt) | 2005-07-05 |
KR20060002728A (ko) | 2006-01-09 |
CN1675189A (zh) | 2005-09-28 |
EP1539723A1 (en) | 2005-06-15 |
CA2495492A1 (en) | 2004-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL166412A0 (en) | Novel use of benzothiazole derivatives | |
SE0202462D0 (sv) | Novel use | |
IL150635A0 (en) | Novel use of phenylheteroalkylamine derivatives | |
MY157949A (en) | Thioxanthine derivatives as myeloperoxidase inhibitors | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
NO20055565L (no) | Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO) | |
MY140638A (en) | New heterocyclic compounds, which are active as inhibitors of beta-lactamases | |
GB0112348D0 (en) | Compounds | |
MY133527A (en) | Isoquinoline derivatives | |
MX2007006744A (es) | Derivados de hidantoina utiles como inhibidores de metaloproteinasa. | |
MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
IL150640A0 (en) | Novel use of phenylheteroalkylamine derivatives | |
NO20045353L (no) | Orto-substituerte benzosyrederivater for behandling av insulinresistens | |
BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios | |
YU30602A (sh) | Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima | |
SE0201193D0 (sv) | Novel use |